Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Other

If ‘other’, further details on the scope of the study

Nintedanib associated diarrhoea control

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Observational new data PASS
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

100
Study design details

Main study objective

To describe the proportion of patients who achieve diarrhoea control while taking a nintedanib dose of 150 mg bid at 12-week follow up in patients with IPF and other PPF reporting a first episode of nintedanib-associated diarrhoea at study baseline.

Outcomes

Achievement of diarrhoea control (yes/no), defined as the passage of less than 3 loose or liquid stools in a 24-hour period (loose or liquid stools defined as stools with a BSFS of 6 or 7 points (17))while being treated with 150 mg bid of nintedanib, at 12-week follow-up. 1. Absolute change in the proportion of patients taking optimal nintedanib dose (150 mg bid) at 12-week follow-up referent to baseline 2. Absolute change in BSFS score at week 12 follow-up referent to baseline 3. Absolute change in number of stools per day at 12-week follow-up referent to baseline 4. Absolute change in current body weight (in kilograms) at 12-week And 6 more

Data analysis plan

Descriptive statistics will be presented as absolute (counts) and relative frequencies (proportions) for categorical variables, and mean, standard deviation, median, 25 and 75 quartiles, and minimum, and maximum values for continuous variables.